1.Clinical study on opioid polypeptides involved in epidemic encephalitis-B pathogenesis.
Chuande ZHUGE ; Lin DENG ; Xisheng QIU
Chinese Journal of Practical Internal Medicine 2001;0(10):-
Objectives In order to study the endogenous opioid polypeptides involved in pathogenesis of epidemic encephalitis-B and the clinical therapeutic efficacy.Methods ①Leucine-enkephalin,?-endophin and Dynorphin levels in plasma and and CSF of patients with epidemic encephalitis-B during critical stage and convalescent stage were measured by radio-immunoassay.②Naloxone therapeutic efficacy in patients with epidemic encephalitis-B were investigated.Results Opioid polypeptides levels In plasma and CSF were significantly higher in critical stage and dropped to normal levels in convalescent stage.③We demonstrated that endogenous opioid polypeptides special antagnoist agent-Naloxone was a very important therapy agent for epidemic encephalitis-B patients.Therapy group efficacy was significantly better than control group.Conclusions These results demonstrate that endogenous opioid polypeptides involves in the physiopathologic changes of epidemic encephalitis-B.
2.Lamivudine Alone or in Combination with Bicyclol to Treat Chronic Viral Hepatitis B:A Clinical Study
Xuefa WAN ; Zaijiao YANG ; Liming ZHANG ; Yufang ZHU ; Chuande ZHUGE
Chinese Journal of Nosocomiology 2006;0(07):-
OBJECTIVE To survey the therapeutic effect of lamivudine alone or in combination with bicyclol on chronical viral hepatitis B.METHODS Ninety patients with chronic viral hepatitis B were divided into 3 groups: A,B and C.Patients of group A(n=30) were given each 100mg lamivudine po qd,and 25 mg(bicyclol) po,tid,and the course of treatment lasted 72 weeks.Patients of group B(n=30) were subjected to(lamivudine) treatment alone at the same dosage as that of patients in group A.Patients of group C(n=30) were treated with(conventional) hepatinica and symptomatic therapeutic measures,serving as controls.Changes in serum HBV DNA and liver functions and YMDD mutant were dynamically monitored.RESULTS At the end of the 24,48 and 72 weeks of treatment,the rates of sera to turn negative for HBV DNA were 90.0%,(86.7%,) and(83.3%),(respectively),in patients of group A,and 86.7%,83.3%,and 76.7%,respectively,in patients of group B.The rates of sera to turn negative for HBV DNA,in patients of groups A and B were significantly higher than those in patients of group C(P0.05);at the end of 72 weeks,the rates of YMDD mutant were 16.7% in group A and 36.7% in group B,the rates in group A were significantly higher than in group B((P